Literature DB >> 18666342

Macrolide therapy in airways disease.

Nick R Anthonisen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18666342      PMCID： PMC2677945          DOI： 10.1155/2008/692495

Source DB:  PubMed          Journal:  Can Respir J        ISSN： 1198-2241            Impact factor:   2.409


× No keyword cloud information.
  12 in total

1.  Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial.

Authors:  A Clement; A Tamalet; E Leroux; S Ravilly; B Fauroux; J-P Jais
Journal:  Thorax       Date:  2006-06-29       Impact factor: 9.139

2.  Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells.

Authors:  B M Vanaudenaerde; W A Wuyts; N Geudens; L J Dupont; K Schoofs; S Smeets; D E Van Raemdonck; G M Verleden
Journal:  Am J Transplant       Date:  2006-10-25       Impact factor: 8.086

3.  Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells.

Authors:  H Takizawa; M Desaki; T Ohtoshi; S Kawasaki; T Kohyama; M Sato; M Tanaka; T Kasama; K Kobayashi; J Nakajima; K Ito
Journal:  Am J Respir Crit Care Med       Date:  1997-07       Impact factor: 21.405

4.  Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial.

Authors:  A Equi; I M Balfour-Lynn; A Bush; M Rosenthal
Journal:  Lancet       Date:  2002-09-28       Impact factor: 79.321

5.  Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

Authors:  J Wolter; S Seeney; S Bell; S Bowler; P Masel; J McCormack
Journal:  Thorax       Date:  2002-03       Impact factor: 9.139

6.  A pilot study of low-dose erythromycin in bronchiectasis.

Authors:  K W Tsang; P I Ho; K N Chan; M S Ip; W K Lam; C S Ho; K Y Yuen; G C Ooi; R Amitani; E Tanaka
Journal:  Eur Respir J       Date:  1999-02       Impact factor: 16.671

7.  Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.

Authors:  Lisa Saiman; Bruce C Marshall; Nicole Mayer-Hamblett; Jane L Burns; Alexandra L Quittner; Debra A Cibene; Sarah Coquillette; Ann Yunker Fieberg; Frank J Accurso; Preston W Campbell
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

8.  The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial.

Authors:  Dev Banerjee; David Honeybourne; Omer A Khair
Journal:  Treat Respir Med       Date:  2004

9.  Effect of maintenance azithromycin on established bronchiolitis obliterans syndrome in lung transplant patients.

Authors:  Nancy R Porhownik; Wael Batobara; Wayne Kepron; Helmut W Unruh; Zoheir Bshouty
Journal:  Can Respir J       Date:  2008 May-Jun       Impact factor: 2.409

10.  Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin.

Authors:  Monica Kraft; Gail H Cassell; Juno Pak; Richard J Martin
Journal:  Chest       Date:  2002-06       Impact factor: 9.410
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.